AUTL - Autolus Therapeutics stock tumbles ~20% after hours as co files for stock offering
- Autolus Therapeutics ( NASDAQ: AUTL ) on Thursday said it had commenced a public offering of its American depositary shares.
- U.S.-listed shares of AUTL fell 20.7% to $2.37 in aftermarket trading.
- The size of the proposed offering was yet to be determined.
- AUTL after hours separately announced that an interim analysis of a phase 2 trial of its investigational CAR-T cell therapy obe-cel for the treatment of a type of blood cancer found that the study met its main goal.
- Additionally, AUTL said that it would get $70M in milestone payments from Blackstone Life Sciences.
For further details see:
Autolus Therapeutics stock tumbles ~20% after hours as co files for stock offering